|1.||Brueckner, Bodo: 2 articles (03/2006 - 03/2006)|
|2.||Lyko, Frank: 2 articles (03/2006 - 03/2006)|
|3.||Penter, Livius: 1 article (12/2015)|
|4.||Frede, Ute: 1 article (12/2015)|
|5.||Carell, Thomas: 1 article (12/2015)|
|6.||Hagemeier, Christian: 1 article (12/2015)|
|7.||Maier, Bert: 1 article (12/2015)|
|8.||Hackner, Benjamin: 1 article (12/2015)|
|9.||Truss, Matthias: 1 article (12/2015)|
|10.||Zhang, Xueming: 1 article (10/2015)|
01/01/2014 - "However, additional mechanism might underlie the anti-tumor effects of RG108. "
01/01/2014 - "RG108 is an effective tumor growth suppressor in most PCa cell lines tested. "
03/01/2006 - "Finally, the experiments in cancer cell lines were complemented by a cell-free in vitro assay with purified recombinant DNA methyltransferase, which indicated that RG108 is the only drug capable of direct enzyme inhibition. "
01/01/2014 - "In this study we aimed to evaluate the anti-cancer properties of RG108, a novel non-nucleoside inhibitor of DNA methyltransferases (DNMT), in PCa cell lines. "
03/01/2006 - "Small-molecule inhibitors of DNA methyltransferases such as RG108 represent promising candidates for cancer drug development. "
12/01/2012 - "In this study, we have observed the antileukemic action of two diverse DNMT inhibitors, the nucleoside agent zebularine and the non-nucleoside agent RG108, in human promyelocytic leukemia (PML) HL-60 cells. "
12/01/2012 - "The results confirmed the utility of zebularine and RG108 in combinations with RA and HDAC inhibitors to reinforce differentiation effects in promyelocytic leukemia."
12/01/2012 - "Antileukemic activity of combined epigenetic agents, DNMT inhibitors zebularine and RG108 with HDAC inhibitors, against promyelocytic leukemia HL-60 cells."
|4.||Prostatic Neoplasms (Prostate Cancer)
|1.||DNA (Deoxyribonucleic Acid)
|6.||Histone Deacetylase Inhibitors
|8.||Recombinant DNA (Recombinant DNA Research)